Professor Takaaki Abe and his team discovered that a medicine called lubiprostone, which is normally used to treat ...
A Japanese study suggests that lubiprostone, a common constipation drug, may help slow kidney decline in people with chronic ...
When a phase two clinical trial from Japan suggested that a common constipation medicine might slow the progression of ...
— Albireo subsidiary eligible to receive up to $60 million under agreement — — Decision on Japanese New Drug Application for elobixibat expected in first half of 2018 — BOSTON, Jan. 03, 2018 (GLOBE ...
Sucampo Pharma, Ltd., a wholly owned subsidiary of Sucampo Pharmaceuticals, Inc. (SPI) has received approval from the Ministry of Health, Labor and Welfare in Japan for Amitiza (lubiprostone), a ...
A common constipation drug, lubiprostone, shows remarkable potential in slowing kidney function decline for chronic kidney ...
Chronic kidney disease (CKD) affects people across the globe and often progresses to the point where patients rely on routine dialysis to survive ...
Researchers have discovered that a common constipation drug can slow kidney decline in CKD patients. This is a new frontier ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback